{"id":"NCT02914509","sponsor":"Ocular Therapeutix, Inc.","briefTitle":"Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT","officialTitle":"A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-07","primaryCompletion":"2019-03-30","completion":"2019-03-30","firstPosted":"2016-09-26","resultsPosted":"2021-10-11","lastUpdate":"2021-10-11"},"enrollment":565,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Travoprost","otherNames":[]},{"type":"OTHER","name":"Placebo Vehicle","otherNames":[]}],"arms":[{"label":"OTX-TP (sustained release travoprost) Intracanalicular Depot","type":"EXPERIMENTAL"},{"label":"PV (Placebo Vehicle) Intracanalicular Depot","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension","primaryOutcome":{"measure":"Mean IOP","timeFrame":"Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit","effectByArm":[{"arm":"OTX-TP (Sustained Release Travoprost) Intracanalicular Depot","deltaMin":21,"sd":0.2},{"arm":"Placebo Vehicle (PV)","deltaMin":22.9,"sd":0.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":348},"commonTop":["Adverse Event"]}}